Latest news with #Claromer™
Yahoo
11-06-2025
- Business
- Yahoo
Maxwell Targets $500B Cosmetics Market with Microbiome-Friendly Antiseptics
Austin, Texas--(Newsfile Corp. - June 11, 2025) - Maxwell Biosciences, an innovator in technology that behaves like the natural immune system, announces its strategic entry into partnerships and licensing deals in the cosmetics and personal care market with its immune-inspired Claromer™ platform. The company's breakthrough Claromer™ technology is now being tested by some of the top cosmetics companies in the world. Maxwell aims to usher in a new generation of personal care products designed for today's health-conscious consumer. To view an enhanced version of this graphic, please visit: The Opportunity for Something BetterMaxwell's entry into partnerships with the cosmetics industry is about enhancing skin health and longevity at the molecular level. Inspired by the body's natural defenses, Maxwell's technology protects against harmful pathogens and nurtures the skin's healthy microbiome, ensuring a balanced and thriving ecosystem. These products will not be tested on animals. "Our mission has always been to create health for the world, safely and affordably," said J. Scotch McClure, CEO of Maxwell Biosciences. "The cosmetics space is overdue for a revolution in safety and performance. Claromers™ can deliver that—naturally, safely and without harming the skin's delicate ecosystem." Maxwell is moving forward with active collaborations with global leaders in cosmetics. Additional opportunities are now open for strategic partners. To learn more about Maxwell's Claromer™ platform for cosmetics and personal care, visit About Maxwell BiosciencesMaxwell Biosciences is a global health technology company pioneering a new category of immune-inspired small molecules called Claromers™. Designed to mimic and enhance the body's natural defenses, Claromers™ destroy pathogenic bacteria, viruses, fungi and biofilms—without harming healthy cells or the microbiome. Originally developed for critical infectious diseases, Maxwell's technology is now entering commercial deployment across cosmetics, personal care, medical coatings and biodefense. Claromers™ require no refrigeration and are highly stable in even the harshest environments. Backed by a decade of research, a robust patent portfolio and leadership with deep expertise in science, military, AI and global health, Maxwell has collaborative agreements with the US military and governments worldwide. FDA clinical trials are planned for 2026. Non-pharmaceutical commercialization begins in 2025, with pilot access with select partners already underway. Maxwell's AI-first platform enables rapid innovation against the rising threat of resistant pathogens, offering scalable, shelf-stable and microbiome-resilient solutions for a healthier planet. To learn more about Maxwell Biosciences, visit or follow us on X and LinkedIn. ContactPress@ To view the source version of this press release, please visit
Globe and Mail
26-02-2025
- Health
- Globe and Mail
Maxwell Biosciences Secures US Military Research Agreement to Combat Dengue Fever
U.S. Naval Infectious Diseases Diagnostic Laboratory to study dengue fever activity of Claromer antiviral compounds, combatting a rapidly growing mosquito-borne viral infection and a national priority biodefense threat Austin, Texas--(Newsfile Corp. - February 26, 2025) - Maxwell Biosciences, a preclinical drug platform company that develops Claromers TM, synthetic small molecules that mimic and improve upon the compounds of the human immune system, today announced a new collaboration. Maxwell has entered into a Cooperative Research and Development Agreement to develop therapies for dengue virus infections with the Naval Medical Research Command's (NMRC) Naval Medical Infectious Diseases Diagnostic Laboratory (NIDDL). Scientist examines dengue virus in laboratory To view an enhanced version of this graphic, please visit: Located at NMRC's Silver Spring, Maryland headquarters, the NIDDL assists in the detection and identification of high-risk and emerging infectious diseases and will test Maxwell Biosciences' Claromer TM compounds for use as an antiviral therapeutic agent against the four known strains of dengue fever, a mosquito-borne viral infection. "Entering a collaborative research and development agreement with the NMRC and NIDDL demonstrates the remarkable momentum behind Maxwell's Claromer™ biodefense technology," said Scotch McClure, CEO of Maxwell Biosciences. "Dengue fever cases continue to increase worldwide, with 12 million infections reported by the Centers for Disease Control in 2024 in the Americas. Globally, cases of dengue have doubled each year since 2021. At Maxwell, we're honored to partner with the U.S. military to tackle the most difficult diseases that are beyond the capabilities of other pharmaceutical companies. Maxwell is a true pioneer in this space, leading the world in our efforts for developing new, shelf-stable therapeutics against the world's most neglected, dangerous and deadly pathogens." About Dengue Dengue fever is categorized as a Neglected Tropical Disease by the World Health Organization. Dengue virus primarily passes to people from the bite of an infected Aedes species mosquito, the same mosquitos that carry Zika and Chikungunya. [ 1 ] Symptoms of dengue fever include high fever, severe headaches, pain behind the eyes, muscle and joint pain, nausea, vomiting, swollen glands, rash and death. Most cases are mild and last about two weeks. Severe dengue has more serious symptoms and often impacts those who are infected with dengue more than once. [ 2 ] Dengue is now the fastest-growing mosquito-borne illness in the world. [ 3 ] Between January and September 2024, 12.7 million cases were reported-double the total for all of 2023—with the highest concentration in the Americas. This surge is due in part to expanding mosquito habitats resulting from climate change. Dengue is endemic in 130 countries. [ 4 ] About the NMRC NMRC is engaged in a broad spectrum of activities, such as basic science in the laboratory, field studies in austere and remote areas of the world and investigations in operational environments. In support of the Navy, Marine Corps and joint U.S. warfighters, researchers study infectious diseases, biological warfare detection and defense, combat casualty care, environmental health concerns, aerospace and undersea medicine, medical modeling, simulation, operational mission support, epidemiology and behavioral sciences. NMRC's NIDDL serves in the detection and identification of high-risk and emerging infectious diseases. It also conducts surveillance efforts for Department of Defense frontline providers and public health professionals in support of health protection for active-duty military members and military health system beneficiaries. About Maxwell Biosciences Founded in 2016, Maxwell Biosciences is a preclinical drug platform company that develops Claromers TM, synthetic small molecules that mimic and improve upon the natural immune system. Inspired by nature, these deep tech breakthrough molecules have been shown to be effective against Ebola, zika, herpes, dengue, pan-coronavirus and pan-influenza A (avian, swine and human) in destroying viruses, but also all tested bacteria, fungi and biofilms with a single compound, while safely preserving healthy cells. This new "One Drug for Many Bugs" technology has been shown to be well-tolerated in lab-grown human tissue and in multiple animal studies and is shelf-stable. The compounds imitate key components of the innate immune system: humanity's greatest asset in fighting disease. Maxwell's technology is protected by numerous granted and pending patents and is led by a world-class team of scientists, military veterans and experienced life science executives. Disclaimer The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the U.S. Government.
Associated Press
26-02-2025
- Health
- Associated Press
Maxwell Biosciences Secures US Military Research Agreement to Combat Dengue Fever
U.S. Naval Infectious Diseases Diagnostic Laboratory to study dengue fever activity of Claromer antiviral compounds, combatting a rapidly growing mosquito-borne viral infection and a national priority biodefense threat Austin, Texas--(Newsfile Corp. - February 26, 2025) - Maxwell Biosciences, a preclinical drug platform company that develops Claromers TM, synthetic small molecules that mimic and improve upon the compounds of the human immune system, today announced a new collaboration. Maxwell has entered into a Cooperative Research and Development Agreement to develop therapies for dengue virus infections with the Naval Medical Research Command's (NMRC) Naval Medical Infectious Diseases Diagnostic Laboratory (NIDDL). Scientist examines dengue virus in laboratory To view an enhanced version of this graphic, please visit: Located at NMRC's Silver Spring, Maryland headquarters, the NIDDL assists in the detection and identification of high-risk and emerging infectious diseases and will test Maxwell Biosciences' Claromer TM compounds for use as an antiviral therapeutic agent against the four known strains of dengue fever, a mosquito-borne viral infection. 'Entering a collaborative research and development agreement with the NMRC and NIDDL demonstrates the remarkable momentum behind Maxwell's Claromer™ biodefense technology,' said Scotch McClure, CEO of Maxwell Biosciences. 'Dengue fever cases continue to increase worldwide, with 12 million infections reported by the Centers for Disease Control in 2024 in the Americas. Globally, cases of dengue have doubled each year since 2021. At Maxwell, we're honored to partner with the U.S. military to tackle the most difficult diseases that are beyond the capabilities of other pharmaceutical companies. Maxwell is a true pioneer in this space, leading the world in our efforts for developing new, shelf-stable therapeutics against the world's most neglected, dangerous and deadly pathogens.' About Dengue Dengue fever is categorized as a Neglected Tropical Disease by the World Health Organization. Dengue virus primarily passes to people from the bite of an infected Aedes species mosquito, the same mosquitos that carry Zika and Chikungunya. [ 1 ] Symptoms of dengue fever include high fever, severe headaches, pain behind the eyes, muscle and joint pain, nausea, vomiting, swollen glands, rash and death. Most cases are mild and last about two weeks. Severe dengue has more serious symptoms and often impacts those who are infected with dengue more than once. [ 2 ] Dengue is now the fastest-growing mosquito-borne illness in the world. [ 3 ] Between January and September 2024, 12.7 million cases were reported-double the total for all of 2023—with the highest concentration in the Americas. This surge is due in part to expanding mosquito habitats resulting from climate change. Dengue is endemic in 130 countries. [ 4 ] About the NMRC NMRC is engaged in a broad spectrum of activities, such as basic science in the laboratory, field studies in austere and remote areas of the world and investigations in operational environments. In support of the Navy, Marine Corps and joint U.S. warfighters, researchers study infectious diseases, biological warfare detection and defense, combat casualty care, environmental health concerns, aerospace and undersea medicine, medical modeling, simulation, operational mission support, epidemiology and behavioral sciences. NMRC's NIDDL serves in the detection and identification of high-risk and emerging infectious diseases. It also conducts surveillance efforts for Department of Defense frontline providers and public health professionals in support of health protection for active-duty military members and military health system beneficiaries. About Maxwell Biosciences Founded in 2016, Maxwell Biosciences is a preclinical drug platform company that develops Claromers TM, synthetic small molecules that mimic and improve upon the natural immune system. Inspired by nature, these deep tech breakthrough molecules have been shown to be effective against Ebola, zika, herpes, dengue, pan-coronavirus and pan-influenza A (avian, swine and human) in destroying viruses, but also all tested bacteria, fungi and biofilms with a single compound, while safely preserving healthy cells. This new 'One Drug for Many Bugs' technology has been shown to be well-tolerated in lab-grown human tissue and in multiple animal studies and is shelf-stable. The compounds imitate key components of the innate immune system: humanity's greatest asset in fighting disease. Maxwell's technology is protected by numerous granted and pending patents and is led by a world-class team of scientists, military veterans and experienced life science executives. Contacts Scotch McClure Media Disclaimer The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the U.S. Government.
